MX2024004157A - Inhibidor de wee1 para el cancer. - Google Patents
Inhibidor de wee1 para el cancer.Info
- Publication number
- MX2024004157A MX2024004157A MX2024004157A MX2024004157A MX2024004157A MX 2024004157 A MX2024004157 A MX 2024004157A MX 2024004157 A MX2024004157 A MX 2024004157A MX 2024004157 A MX2024004157 A MX 2024004157A MX 2024004157 A MX2024004157 A MX 2024004157A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- wee1 inhibitor
- pharmaceutically acceptable
- acceptable salt
- wee1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163265438P | 2021-12-15 | 2021-12-15 | |
| PCT/US2022/081596 WO2023114875A1 (en) | 2021-12-15 | 2022-12-14 | Wee1 inhibitor for cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004157A true MX2024004157A (es) | 2024-04-23 |
Family
ID=86773533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004157A MX2024004157A (es) | 2021-12-15 | 2022-12-14 | Inhibidor de wee1 para el cancer. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240335447A1 (https=) |
| EP (1) | EP4447974A4 (https=) |
| JP (1) | JP2024546569A (https=) |
| KR (1) | KR20240119059A (https=) |
| CN (1) | CN118201616A (https=) |
| AU (1) | AU2022414090A1 (https=) |
| CA (1) | CA3235595A1 (https=) |
| MX (1) | MX2024004157A (https=) |
| WO (1) | WO2023114875A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| BR112023000350A2 (pt) | 2020-07-09 | 2023-03-28 | Recurium Ip Holdings Llc | Sais e formas de um inibidor de wee1 |
| WO2025184572A1 (en) * | 2024-03-01 | 2025-09-04 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
| WO2025261307A1 (zh) * | 2024-06-17 | 2025-12-26 | 首药控股(北京)股份有限公司 | 治疗肿瘤的药物组合及用途 |
| CN121159528A (zh) * | 2025-07-25 | 2025-12-19 | 天津医科大学总医院 | 一种PROTAC化合物及其制备方法和作为靶向PTRF/Cavin1的降解剂的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017003502A1 (en) * | 2015-07-01 | 2017-01-05 | Dignity Health | Systems and methods for treating cancer |
| MX2020009372A (es) * | 2018-03-09 | 2020-10-14 | Recurium Ip Holdings Llc | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. |
-
2022
- 2022-12-14 JP JP2024524692A patent/JP2024546569A/ja active Pending
- 2022-12-14 EP EP22908681.4A patent/EP4447974A4/en active Pending
- 2022-12-14 CN CN202280073343.3A patent/CN118201616A/zh active Pending
- 2022-12-14 AU AU2022414090A patent/AU2022414090A1/en active Pending
- 2022-12-14 CA CA3235595A patent/CA3235595A1/en active Pending
- 2022-12-14 MX MX2024004157A patent/MX2024004157A/es unknown
- 2022-12-14 KR KR1020247013738A patent/KR20240119059A/ko active Pending
- 2022-12-14 WO PCT/US2022/081596 patent/WO2023114875A1/en not_active Ceased
-
2024
- 2024-06-14 US US18/743,544 patent/US20240335447A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4447974A4 (en) | 2025-11-26 |
| KR20240119059A (ko) | 2024-08-06 |
| US20240335447A1 (en) | 2024-10-10 |
| AU2022414090A1 (en) | 2024-04-18 |
| CA3235595A1 (en) | 2023-06-22 |
| JP2024546569A (ja) | 2024-12-26 |
| WO2023114875A1 (en) | 2023-06-22 |
| CN118201616A (zh) | 2024-06-14 |
| EP4447974A1 (en) | 2024-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004157A (es) | Inhibidor de wee1 para el cancer. | |
| CA3139348A1 (en) | Heterocyclic compounds for inhibiting ras and uses thereof | |
| BR112022003165A2 (pt) | Método de tratamento de cânceres associados a kras | |
| WO2019169065A3 (en) | Wee1 kinase inhibitors and methods of treating cancer using the same | |
| EP4552631A3 (en) | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer | |
| TR201900306T4 (tr) | Mek inhibitörlerini kullanma yöntemleri. | |
| TN2012000622A1 (en) | Combinations of kinase inhibitors for the treatment of cancer | |
| MX2022007626A (es) | Combinaciones. | |
| CR20240296A (es) | Inhibidores parp1 | |
| MX2022007628A (es) | Combinaciones. | |
| MX2022010975A (es) | Inhibidores de egfr, kras, braf y otras dianas y uso de estos. | |
| SG164378A1 (en) | Compounds for the treatment of proliferative disorders | |
| DE602007014186D1 (de) | Triazin-11-beta-hydroxysteroid-dehydrogenase-artige hemmer | |
| EA201490472A1 (ru) | Комбинированная терапия рака hsp90-ингибитором и антиметаболитом | |
| MX2021010321A (es) | Compuestos macrociclicos. | |
| WO2022240971A3 (en) | Kras g12d inhibitors and uses thereof | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| CO2023001668A2 (es) | Derivados de 1h-benzo[d]imidazol como inhibidores de tlr9 para el tratamiento de fibrosis | |
| CR20240014A (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| BR112022010278A2 (pt) | Terapia combinada que envolve compostos macrocíclicos de diarila | |
| MX2022007623A (es) | Combinaciones. | |
| TW200716570A (en) | Compounds for the treatment of proliferative disorders | |
| MX2025012153A (es) | Inhibidores de cdk2 | |
| WO2021163683A8 (en) | Inhibitors of nicotinamide n-methyltransferase, compositions and uses thereof | |
| MX2022010912A (es) | Combinacion de un inhibidor de desmetilasa-1 especifica de lisina (lsd-1) y nivolumab para usarse en el tratamiento de cancer de pulmon de celulas peque?as (sclc) o cancer de pulmon de celulas no peque?as escamosas (sqnsclc). |